ArticleGenome medicine2026
Leveraging tumor dynamics to discover mutations influencing progression and treatment response for precision oncology.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent research in precision oncology focuses on progression-free survival (PFS) and overall survival (OS) as the key outcomes. This stands in stark contrast to the primary outcomes guiding cancer treatment in the clinic- dynamic changes in tumor size in response to treatment. While PFS and OS are meaningful, highly interpretable and easily collected, we hypothesize that revealing associations between somatic mutations and tumor size dynamics can uncover genetic factors that can influence treatment response and generate hypotheses for future clinical investigation, while further improving our understanding of tumor biology.
methodsWe propose and benchmark a new statistical framework - Andersen-Gill based Tumor Dynamics (AG-TD) to model recurrent outcomes and apply it to data from ~ 17 K radiology reports of patients with non-small cell lung cancer undergoing routine treatment at the Dana-Farber Cancer Institute. Our approach enables modeling recurrent outcomes while considering the time-dependent nature of biomarker-treatment interaction, patient mortality, and loss to follow-up.
resultsWe identify 27 somatic mutations that lead to differential response to common treatments including both protective and hazardous effects. Among these, deletions in MYBL1 and GATA3 were independently validated by replication in an external EGFR-TKI drug sensitivity screen, reaching Bonferroni correction significance. We also identify 13 somatic mutations associated with differential rates of progression and response during the entire treatment course, of which 9 are undetectable using conventional OS or PFS models. We further verify that the results are consistent in a homogeneous sub-cohort of advanced stage (3 and 4) patients only.
conclusionsOverall, we demonstrate the potential for using longitudinal outcomes in cancer genetic studies to complement traditional survival-based analyses, and to enable systematic identification of candidate gene-treatment interactions for future validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.